Frederic R. King

  • Citations Per Year
Learn More
PURPOSE Estimate rate of laxative inadequate response (LIR) over time among patients with chronic noncancer pain with opioid-induced constipation (OIC). METHODS A prospective longitudinal study was conducted in United States, Canada, Germany, and United Kingdom. Patients on opioid therapy for ≥4 weeks for chronic noncancer pain and OIC completed an(More)
• Data were pooled from 2 randomized, double-blind, placebocontrolled phase 3 studies of naloxegol conducted over 12 weeks in patients with noncancer pain and OIC (N=1352; intent-to-treat [ITT], N=1337 [KODIAC-04, NCT01309841; KODIAC-05, NCT01323790]).3 – EQ-5D4 scores were collected at baseline, week 4, and week 12 and converted into estimates of utility(More)
INTRODUCTION Opioid-induced constipation (OIC) is the most common side effect of opioid treatment. Treatment for OIC typically involves a laxative. However, some patients have an inadequate response to these (laxative inadequate responders, or LIR). This has led to the development of treatments such as naloxegol. This analysis estimates the impact of(More)
BACKGROUND AND OBJECTIVES Opioid-induced constipation (OIC) is the most common adverse effect reported in patients receiving opioids to manage pain. Initial treatment with laxatives provides inadequate response in some patients. Naloxegol is a peripherally acting µ-opioid receptor antagonist used to treat patients with inadequate response to laxative(s)(More)
BACKGROUND Little is known regarding the burden of opioid-induced constipation (OIC) among patients who suffer from cancer-related pain. METHODS A prospective longitudinal study was conducted among cancer patients in the United Kingdom (UK), Canada, and Germany, which included medical record data abstraction, Internet-based patient surveys, and physician(More)
  • 1